Showing results (631-640 of 746) with videos related to
Sort By:
Pageof 75
The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences|February 15, 2026
Benefits of Oral Nitrite Supplementation on Mitochondrial Respiration and Physical Function In Older AdultsDaniel E Forman, Subashan Perera, Sruti Shiva, et al.American Journal of Physiology. Endocrinology and Metabolism|May 12, 2016
Reduced intestinal lipid absorption and body weight-independent improvements in insulin sensitivity in high-fat diet-fed Park2 knockout miceDiana K Costa, Brydie R Huckestein, Lia R Edmunds, et al.Journal of Applied Genetics|August 12, 2025
NGS sequencing reveals the cause of hearing loss in a group of Polish patients with an isolated, non-DFNB1 hearing lossKatarzyna Niepokój, Agnieszka Magdalena Rygiel, Katarzyna Wertheim-Tysarowska, et al.Leukemia & Lymphoma|May 31, 2017
Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimusGeorg Hess, Simon Rule, Wojciech Jurczak, et al.The Journal of Biological Chemistry|August 12, 2011
Influence of the hepatic eukaryotic initiation factor 2alpha (eIF2alpha) endoplasmic reticulum (ER) stress response pathway on insulin-mediated ER stress and hepatic and peripheral glucose metabolismAndreas L Birkenfeld, Hui-Young Lee, Sachin Majumdar, et al.JCI Insight|December 22, 2020
Tregs facilitate obesity and insulin resistance via a Blimp-1/IL-10 axisLisa Y Beppu, Raja Gopal Reddy Mooli, Xiaoyao Qu, et al.Biorxiv : the Preprint Server for Biology|February 20, 2025
Cardiac-specific GCN5L1 deficiency promotes MASLD in HFpEFParamesha Bugga, Bellina A S Mushala, Michael W Stoner, et al.Hemasphere|August 7, 2024
The PI3Kδ inhibitor zandelisib on intermittent dosing in relapsed/refractory follicular lymphoma: Results from a global phase 2 studyAndrew D Zelenetz, Wojciech Jurczak, Vincent Ribrag, et al.The Lancet. Oncology|February 6, 2025
Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 studyMichael Wang, Wojciech Jurczak, Marek Trneny, et al.The New England Journal of Medicine|February 20, 2025
Fixed-Duration Acalabrutinib Combinations in Untreated Chronic Lymphocytic LeukemiaJennifer R Brown, John F Seymour, Wojciech Jurczak, et al.Pageof 75